Abstract
Wnt5a is a representative ligand that activates the β-catenin-independent pathway in Wnt signaling. Although it has been reported that abnormal activation of the Wnt/β-catenin-dependent pathway is often observed in human prostate cancer, the involvement of the β-catenin-independent pathway in this cancer is unclear. Abnormal expression of Wnt5a and β-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses. Simultaneous expression of Wnt5a and β-catenin was observed in only five cases, suggesting their exclusive expression. The positive detection of Wnt5a was correlated with high Gleason scores and biochemical relapse of prostate cancer, but that of β-catenin was not. Knockdown and overexpression of Wnt5a in human prostate cancer cell lines reduced and stimulated, respectively, their invasion activities, and the invasion activity required Frizzled2 and Ror2 as Wnt receptors. Wnt5a activated Jun-N-terminal kinase through protein kinase D (PKD) and the inhibition of PKD suppressed Wnt5a-dependent cell migration and invasion. In addition, Wnt5a induced the expression of metalloproteinase-1 through the recruitment of JunD to its promoter region. These results suggest that Wnt5a promotes the aggressiveness of prostate cancer and that its expression is involved in relapse after prostatectomy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angel P, Baumann I, Stein B, Delius H, Rahmsdorf HJ, Herrlich P . (1987). 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol Cell Biol 7: 2256–2266.
Bernard P, Harley VR . (2007). Wnt4 action in gonadal development and sex determination. Int J Biochem Cell Biol 39: 31–43.
Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S . (2008). Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 283: 6232–6240.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH et al. (2000). Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18: 1164–1172.
Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T . (2005). Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65: 9142–9146.
Doyle GA, Pierce RA, Parks WC . (1997). Transcriptional induction of collagenase-1 in differentiated monocyte-like (U937) cells is regulated by AP-1 and an upstream C/EBP-β site. J Biol Chem 272: 11840–11849.
Egeblad M, Werb Z . (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174.
Gleason DF, Mellinger GT . (1974). Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58–64.
Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR et al. (2003). The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem 278: 10304–10313.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC . (2003). Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517–523.
Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, Lang SH . (2002). Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86: 1136–1142.
Hsing AW, Tsao L, Devesa SS . (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85: 60–67.
Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H et al. (2005). Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor—an expression in non-small-cell lung cancer. J Clin Oncol 23: 8765–8773.
Hurlstone A, Clevers H . (2002). T-cell factors: turn-ons and turn-offs. EMBO J 21: 2303–2311.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
Kawano Y, Kypta R . (2003). Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627–2634.
Kikuchi A . (2003). Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 94: 225–229.
Kikuchi A, Yamamoto H . (2008). Tumor formation due to abnormalities in the β-catenin-independent pathway of Wnt signaling. Cancer Sci 99: 202–208.
Kikuchi A, Yamamoto H, Sato A . (2009). Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 19: 119–129.
Kobayashi T, Hino S-I, Oue N, Asahara T, Zollo M, Yasui W et al. (2006). Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol 26: 898–911.
Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, Brabant G . (2005). Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144–2154.
Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T et al. (2006). Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66: 10439–10448.
Kurayoshi M, Yamamoto H, Izumi S, Kikuchi A . (2007). Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem J 402: 515–523.
Logan CY, Nusse R . (2004). The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781–810.
Mantel N . (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170.
Masckauchan TN, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL, Li CM et al. (2006). Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell 17: 5163–5172.
Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B et al. (2003). The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 8: 645–654.
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al. (1997). Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445–1451.
Polakis P . (2000). Wnt signaling and cancer. Genes Dev 14: 1837–1851.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597.
Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S et al. (2006). Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA 103: 5454–5459.
Rozengurt E, Rey O, Waldron RT . (2005). Protein kinase D signaling. J Biol Chem 280: 13205–13208.
Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A . (2010). Wnt5a regulates distinct signaling pathways by binding to Frizzled2. EMBO J 29: 41–54.
Sobin LH, Wittekind CH . (2002). TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss, Inc.: New York.
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815–2825.
Veeman MT, Axelrod JD, Moon RT . (2003). A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev Cell 5: 367–377.
Verras M, Brown J, Li X, Nusse R, Sun Z . (2004). Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64: 8860–8866.
Wang HY, Liu T, Malbon CC . (2006). Structure-function analysis of Frizzleds. Cell Signal 18: 934–941.
Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J et al. (2007). Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26: 6560–6565.
Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M et al. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279–288.
Wu JY, Lu H, Sun Y, Graham DY, Cheung HS, Yamaoka Y . (2006). Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori-stimulated matrix metalloproteinase 1 expression. Cancer Res 66: 5111–5120.
Yamamoto H, Kitadai Y, Oue N, Ohdan H, Yasui W, Kikuchi A . (2009). Laminin γ2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology 137: 242–252, 252 e241-246.
Yardy GW, Brewster SF . (2005). Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8: 119–126.
Zeng ZZ, Jia Y, Hahn NJ, Markwart SM, Rockwood KF, Livant DL . (2006). Role of focal adhesion kinase and phosphatidylinositol 3′-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells. Cancer Res 66: 8091–8099.
Acknowledgements
This work was supported by Grants-in-Aid for Scientific Research and for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan (2007, 2008, 2009), The YASUDA Medical Foundation (2006) and Uehara Memorial Foundation (2008).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Yamamoto, H., Oue, N., Sato, A. et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29, 2036–2046 (2010). https://doi.org/10.1038/onc.2009.496
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.496
Keywords
This article is cited by
-
Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer
Scientific Reports (2021)
-
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance
Discover Oncology (2021)
-
The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment
Cancer and Metastasis Reviews (2020)
-
Src and Fyn define a new signaling cascade activated by canonical and non-canonical Wnt ligands and required for gene transcription and cell invasion
Cellular and Molecular Life Sciences (2020)
-
WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages
British Journal of Cancer (2018)